NuMedii is at the forefront of integrating Big Data, Artificial Intelligence (AI), and systems biology to revolutionize drug discovery, particularly for precision therapies aimed at addressing significant unmet medical needs. Since its inception in 2010, the company has developed a proprietary technology known as AIDD (Artificial Intelligence for Drug Discovery), which leverages vast amounts of genomic, molecular, and biomedical data to uncover new therapeutic options. By creating a structured data resource that encompasses hundreds of diseases and thousands of compounds, NuMedii's AIDD technology enables the exploration of poly-pharmacology profiles, enhancing therapeutic efficacy by targeting multiple disease pathways simultaneously.

The company recognizes the complexities of modern biomedical data, which necessitate advanced computational methods to process and analyze. NuMedii employs a range of AI techniques, from classical machine learning to deep learning systems, to identify patterns and correlations within extensive datasets. This approach not only accelerates drug discovery and reduces research and development costs but also aims to improve patient outcomes by identifying specific patient subgroups that may benefit from tailored therapies. By harnessing the power of Big Data and AI, NuMedii is committed to advancing precision therapeutics and expanding its pipeline in rare diseases and oncology.

United States

NuMedii is a biopharmaceutical company that discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success.

NuMedii

Company Details